Integral Health Asset Management LLC Invests $11.02 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Integral Health Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 500,000 shares of the company’s stock, valued at approximately $11,020,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Iron Triangle Partners LP raised its position in shares of Teva Pharmaceutical Industries by 13.2% during the 4th quarter. Iron Triangle Partners LP now owns 2,200,036 shares of the company’s stock valued at $48,489,000 after buying an additional 256,246 shares during the period. Janus Henderson Group PLC raised its position in shares of Teva Pharmaceutical Industries by 40.6% during the 4th quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company’s stock valued at $148,497,000 after buying an additional 1,945,688 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $332,000. Graham Capital Management L.P. raised its position in shares of Teva Pharmaceutical Industries by 148.4% during the 4th quarter. Graham Capital Management L.P. now owns 76,232 shares of the company’s stock valued at $1,680,000 after buying an additional 45,542 shares during the period. Finally, Focus Partners Wealth raised its position in shares of Teva Pharmaceutical Industries by 8.7% during the 4th quarter. Focus Partners Wealth now owns 38,335 shares of the company’s stock valued at $845,000 after buying an additional 3,071 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 6.3%

Shares of NYSE TEVA opened at $16.94 on Monday. The firm has a market cap of $19.21 billion, a price-to-earnings ratio of -11.68, a PEG ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The business’s 50 day moving average is $15.18 and its two-hundred day moving average is $17.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the company earned $0.48 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average price target of $23.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.